Business Wire | Jan 14, 2021 04:45PM EST

Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

Jan. 14, 2021

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 14, 2021--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET.

A live audio webcast of the presentation will be available on Geron's website, www.geron.com/investors/events. A replay of the webcast will be available on the Company's website for 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005809/en/

CONTACT: Olivia Bloom Chief Financial Officer investor@geron.com media@geron.com